Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy With or Without Amifostine in Childhood Hepatoblastoma
NCT00003994Phase 3Completed
- Sponsor
- Children's Oncology Group
- Start
- Mar 1999
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of amifostine in hepatoblastoma (4 arms), sponsored by Children's Oncology Group. Primary endpoints: Event-free survival rates at 8 years and Toxicity rates assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC) at 8 years. Started Mar 1999; status: completed.
02
Drugs
amifostine
03
Conditions
hepatoblastoma
Beyond the preview
Go deeper on NCT00003994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003994.